biotech
<a href="https://www.fiercebiotech.com/biotech/blackstone-invests-250m-anagram-reduce-burden-cf-complication" hreflang="en">Blackstone invests $250M in Anagram to reduce burden of cystic fibrosis complication</a>
FierceBiotech
May 11, 2026 · 27s listen
Listen · FierceBiotech
<a href="https://www.fiercebiotech.com/biotech/blackstone-invests-250m-anagram-reduce-burden-cf-complication" hreflang="en">Blackstone invests $250M in Anagram to reduce burden of cystic fibrosis complication</a>
0:00-0:27
Live · Kokoro-82M
Audio pre-rendered by Storyflo · cached + delivered from the edge
For people living with exocrine pancreatic insufficiency due to cystic fibrosis, the only treatment option is a regimen that can include up to 40 pills a day. With a $250 million investment from Blackstone Life Sciences, Anagram Therapeutics hopes to reduce that pill burden to just three pills daily.
Share
Send this story to anyone — or drop the embed into a blog post, Substack, Notion page. Every play sends rev-share back to FierceBiotech.
Heard via Storyflo
Get audio versions of every article you read.
Pick what matters — your audio curator gets you into your daily flo.